Join the 'Peginesatide' group to help and get support from people like you.
Posted 16 Feb 2016 by Drugs.com
MONDAY, Feb. 15, 2016 – The pricey anemia drugs often given to people with chronic kidney disease may make no difference in how they feel day to day, a new research review confirms. Researchers said the study results back up current guidelines on how to use the drugs, called erythropoietin-stimulating agents (ESAs). These include the injection drugs marketed under the names Procrit, Epogen and Aranesp. Patients may still benefit from the medications because they reduce the need for blood transfusions to treat severe anemia, said Dr. Navdeep Tangri, senior researcher on the study. "But this should close the book on the idea that these drugs help with exhaustion and improve patients' quality of life," said Tangri, an attending doctor at Seven Oaks General Hospital Renal Program in Manitoba, Canada. However, one expert argued that while on average, that is true, some patients do feel ... Read more
Related support groups: Anemia, Renal Failure, Chronic Kidney Disease, Aranesp, Procrit, Peritoneal dialysis, Epogen, Renal Osteodystrophy, Mircera, Darbepoetin Alfa, Anemia Associated with Chronic Disease, Epoetin Beta-Methoxy Polyethylene Glycol, Epoetin Alfa, Omontys, Peginesatide, Hyperphosphatemia of Renal Failure
FDA Medwatch Alert: Omontys (peginesatide) Injection by Affymax and Takeda: Recall of All Lots - Serious Hypersensitivity Reactions
Posted 25 Feb 2013 by Drugs.com
ISSUE: Affymax, Inc. and Takeda Pharmaceutical Company Limited along with the U.S. Food and Drug Administration (FDA) are informing the public of a voluntary recall of all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. To date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration. The reported serious hypersensitivity reactions have occurred within 30 minutes after such administration of Omontys. There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session. Since launch, more than 25,000 patients have received Omontys in the postmarketing setting. The rate of overall hypersensitivity re ... Read more